|
|
Volumn 83, Issue 12, 1998, Pages 2588-2596
|
|
What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis
a
a
|
|
Author keywords
Anemia; Cancer; Cost benefit; Epoetin alfa; Willingness to pay
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
RECOMBINANT ERYTHROPOIETIN;
ADULT;
ANEMIA;
ARTICLE;
BLOOD TRANSFUSION;
BONE MARROW SUPPRESSION;
CANCER;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG INDUCED DISEASE;
HUMAN;
MAJOR CLINICAL STUDY;
PRIORITY JOURNAL;
ANEMIA;
ANTINEOPLASTIC AGENTS;
CISPLATIN;
COST-BENEFIT ANALYSIS;
EPOETIN ALFA;
ERYTHROCYTE TRANSFUSION;
FEMALE;
HEALTH SERVICES NEEDS AND DEMAND;
HEMATINICS;
HUMANS;
INCOME;
LIFE EXPECTANCY;
MALE;
MIDDLE AGED;
MULTIVARIATE ANALYSIS;
NEOPLASMS;
PRESCRIPTION FEES;
SENSITIVITY AND SPECIFICITY;
SOCIOECONOMIC FACTORS;
|
|
EID: 0032535456
PISSN: 0008543X
EISSN: None
Source Type: Journal
DOI: 10.1002/(SICI)1097-0142(19981215)83:12<2588::AID-CNCR26>3.0.CO;2-M Document Type: Article |
|
Times cited : (52)
|
|
References (21)
|
